U.S. allies’ drug pricing strategies are not sustainable for long-term success, and that’s adversely leading to higher prescription costs at home and abroad, FDA Commissioner Dr. Scott Gottlieb told CNBC on Tuesday.
Europeans “do underpay relative to us for branded drugs and that’s in part because they do put price controls and utilization restrictions on those drugs,” Gottlieb said in a “Squawk Box” interview. “But they’re overpaying relative to us on generic drugs.”